Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Online Publication Date2016-08-08
Print Publication Date2016-12
Permanent link to this recordhttp://hdl.handle.net/10754/620939
MetadataShow full item record
CitationGadhoum SZ, Madhoun NY, Abuelela AF, Merzaban JS (2016) Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy. Leukemia. Available: http://dx.doi.org/10.1038/leu.2016.221.
SponsorsThis work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.